Sickle Cell Awareness Thread: Sickle Cell Awareness Month 2023! UPDATE: FDA APPROVES GENE THERAPY

RoadRage

the voice of reason
BGOL Investor
Thanks so much for this thread. It ought to be stickied every so often. I have the trait, passed it on to my son, who met a girl who also has it and they produced the apple of my eye, my grandson. At about 3 months, he started to have crises. We thought he was gone about 20 times up to the age of 2. We live near Johns Hopkins Medical. A hematologist who had studied SCD in Kingston, Jamaica insisted that we have his spleen removed. So, he has no organ that produces red blood cells, but also no place for the sickled cells to aggregate and cause a crisis. He gets a pneumococcal shot every two years and penicillin daily to reduce the threat of infection. But, they introduced him into Infusion Therapy. He gets a transfusion that basically replaces 80% of his blood every 25-30 days. He is 19 and just finished his freshman year in college. He seldom has severe pain (knock on wood), but takes a drug to reduce iron build up caused by the transfusions. Otherwise, he's a normal kid that tends to get a little tired if he exerts himself. My son works for the government and has top of the line insurance. And, Hopkins Pediatric is 25 minutes from my house and an hour from his dorm. I cannot imagine him surviving without the care he has had via the ability to pay with our insurance. When he is getting close to transfusion time, he tends to get priapism (dick hard all the time), but he's a bit tired so girlfriend has to ride him. BTW, I can see how the vampire legend started among Mediterranean peoples. When he gets transfused, he has super energy for the first 15 days or so.
Dude I cannot imagine going through that much for so long, but at least he is ok and the procedure is working. All I can say is people who are healthy and never experienced anything like this, especially with a child, have no idea what it is like and the importance of have good doctors who know what they are doing.
God bless you and your family and may he continue to respond well to the treatment...
 

sherminator

They hate to see us wiiiiinnnniiinnng
Registered
It was a genetic adaptation to malaria, people closest to the equator blood cells were sickle shaped to prevent the the parasite from mosquitoes that cause malaria, from attaching to the blood cell
 

water

Transparent, tasteless, odorless
OG Investor
Damn shit is crazy.

Where is oprah and bob Johnson with their money for research?

Can diet help those with it?

I literally know no none with sickle cell disease
 

playahaitian

Rising Star
Certified Pussy Poster
New study may help doctors to better treat children who cope with chronic pain
December 9, 2015
A new study describes the development of pediatric pain measures for a National Institutes of Health Initiative aimed at helping doctors better evaluate and therefore better treat children who cope with chronic pain. Based on face-to-face interviews with pediatric patients, the study better captured the young patient's perspective of living with chronic pain.

An article by researchers in the University of Cincinnati's Department of Anthropology, UC College of Medicine Department of Pediatrics, Cincinnati Children's Hospital Medical Center and Emory University School of Medicine is published in the current issue of the Journal of Pain.

Lead author Jeffrey Jacobson, a UC associate professor of anthropology, says the interdisciplinary study was based on individual and focus group interviews with 32 children and with parents of children with chronic pain, including children affected by juvenile arthritis, sickle cell anemia and cerebral palsy.

The study was conducted to evaluate pain measures developed by the Patient Reported Outcomes Measurement Information System (PROMIS) under the National Institutes of Health. PROMIS is an initiative to create a set of freely available, broadly applicable and high-quality patient-reported outcomes - measures that can be used within and across disease conditions throughout a patient's lifetime.

"Pain is not something that can be objectively measured, and patient-reported measures are therefore essential for research and clinical assessment," explains Jacobson. "Our study focused on how children aged 8-to-18 experience and talk about their pain and on the kinds of language and vocabulary they like to use. "For example," he added, " We found that many questions or items from pain measures used with adults, describing pain as 'gnawing or suffocating,' made younger children uncomfortable. They appeared to relate that to a monster or someone doing something to them. They also have a more limited vocabulary than adults, particularly in relation to the more abstract language of pain quality."


The paper describes the different categories of pain experience and language used by children when they talk about chronic pain, and the fit of these categories with those used by PROMIS:

  • Pain behavior - The child indicates he or she becomes irritable or suffers a lack of appetite (or other behavior) when in pain.
  • Pain interference - The child describes slower movement, such as walking, or lack of energy due to pain interference.
  • Pain quality - The child describes pain as sharp, cutting, dull or achy.
"The fit between PROMIS domains and those used by children was very good," says Jacobson. "However, we also found that among some children, they would say something like, 'I did better when the teacher gave me permission to be a little late for class, because it takes me so long to get there.' So, they're describing how they're managing or coping with pain," says Jacobson.

Other pain-coping strategies included self-distraction and exercise as well as cognitive coping strategies, such as "'keep going, save it for another day,'" states the paper.

The study recommended 13 revisions to the PROMIS pain assessment framework for further study based on children's feedback, including dividing pain quality into two categories - pain sensory quality (punching, twisting, electrical) and affective pain quality, including the question, 'In the past 7 days, did your pain ever feel weird?'

The study also recommended additions to describing pain behavior including:

  • I took breaks
  • I asked for someone to help me
  • I told people I couldn't do things with them
  • I told people I couldn't do my usual chores
  • I tried to think of something nice/fun
  • I went to sleep
  • I had to stop what I was doing
  • I got angry at people
The authors add that their findings on pain coping warrants further study for adding to the PROMIS network.

http://www.news-medical.net/news/20...reat-children-who-cope-with-chronic-pain.aspx
 

playahaitian

Rising Star
Certified Pussy Poster
Children with Chronic Pain
How parents can help them to help themselves

Posted Oct 21, 2013


Taryn Oesch, who developed fibromyalgia at age 13, shared, “My mother forced me up and out, which was the last thing I wanted to do at that time! She’d get me to go for walks with her around the neighborhood, even though I complained the whole time.” Taryn, now in graduate school and working full time, credits her mother’s tenacity for her ability to return to high school (after a period of being home-bound) and to persevere. Her mother, who never doubted her daughter’s experience, heeded her doctor’s words that fibromyalgia would bring pain, whether Taryn was lying on the couch or participating actively in life—and made it her mission to empower her daughter. This involved adaptation, such as having her daughter participate in physical therapy rather than gym class when she returned to school.

Taryn was lucky because her mother coached and encouraged her. However, even the best intentioned parents struggle with the stress and uncertainty involved in caring for children who have chronic pain.

Acknowledge the Difficulties

First of all, parents need to give themselves a break. Accepting that one’s child has a chronic health problem of any kind is a difficult process. Witnessing your child suffering from pain, and associated losses, is understandably painful. A recent study shows that parents experience significant distress around the complex and counterintuitive decisions involved in caring for a child with chronic pain. [1]

Parents are often pulled with some immediacy into advocacy roles for their child, while at the same time, facing their own fears, grief, losses, frustration, anger, inadequacy, uncertainty, and powerlessness. Parents who initially misread their child’s behavior, such as not wanting to go to school, as a “phase,” willfulness, evidence of drug use, or other misinterpretation, may experience shame. Parents who have a painful condition themselves may experience guilt for passing along “responsible” genes. Whatever the circumstances, diagnosis is seldom obvious or predictable, and illness is never anyone’s fault. It is important that parents acknowledge the challenge they face, make room for whatever feelings arise, and practice letting go of self-judgment. Parenting a child (including adult children) who suffers from chronic pain is difficult.

While the specifics may differ based on a child’s health condition, symptom severity, and treatment regimen, parents face questions about when to nurture and when to push. It makes sense that parents may want to shield their children from additional suffering, while worrying that too much insulation can interfere with their growth and development. Conflict over these competing desires can lead to inner turmoil, inconsistency, and also family discord when parents hold opposing views.

See your child, not the illness



135902-135840.jpg

Source:
Figuring out then to coddle and when to foster independence is a central task of parenthood. This becomes additionally challenging when a child is ill. However, studies across a number of pain conditions have found that children fare best and are most adaptive when parents do not focus primarily on their child’s symptoms, allow too frequent avoidance of activities, or exhibit great distress themselves.[2,3,4] In other words, the less that parents emphasize their children’s difficulties the better. Consider how toddlers look expectantly to parents before committing to a reaction themselves. When toddlers stumble, for example, they quickly interpret parents’ verbal and nonverbal cues to assess whether to laugh it off and keep going, or howl until comforted.

Children with chronic illness benefit from parents’ normalizing the situation in an accepting, matter-of-fact way. This is different from ignoring or discounting reports of pain. Parents can acknowledge what a child expresses without escalating or reinforcing distress. Parents’ level of acceptance will come through.

Foster positive self-awareness

The inherent paradoxes of complex pain conditions require the ability to act in counterintuitive ways, such as getting up and moving, despite pain and exhaustion, and also limiting activity, despite pain respites. Parents can help children make sense of their experience. Parent and child both can conduct experiments and develop a corresponding narrative.

article continues after advertisement
For example:

Notice times when your child can engage in activities that positively distract them from pain. Remark on them gently in the moment. Ask questions to understand your child’s experience. Then, use this information to help cultivate self-awareness about the variation of pain:

  • “I know you hurt right now, and don’t feel up to seeing friends. However, last time you didn’t feel up to it, and then later told me that you had a great time with your buddies.”
You can add in more detail that you collect, such as:

  • “It may not feel like it right now. But remember that you told me that your pain went down to a “2” (out of 10) when you were with friends? And it had started at an “8,” right?
Rather than giving the choice of whether or not to go, ask questions that foster problem solving:

  • “What will help you enjoy yourself the most?”
It’s most effective when the child answers this for him or herself. Providing choices when possible can help children feel more responsible and in control.

Parents can plant seeds by sharing observations from comparable situations:

  • “Didn’t you say that the seats in that movie theater were really comfortable?”


article continues after advertisement
135902-135837.jpg

Friendships are important. Help your child connect.

Source:
Encourage them to brainstorm about restorative activities they can enjoy when they return home, such as a hot bath, favorite music, or other pleasant experience. Knowing that something comforting awaits them can increase their willingness to take a risk and participate. This works both as an incentive and as positive behavioral shaping for self-care and balance.

Parents with pain conditions can model positive adaption through engagement and adaptation. How parents demonstrate coping, flexibility, and carving out restorative time to rejuvenate sends a powerful message.

Nurture self-expression



135902-135844.jpg

Source:
Research also shows that the less focused individuals are on symptoms, the better [2,3,4]. Consider ways to help children pursue their interests and passions and explore new ones. Attending to a child's pursuits and achievements reinforces the message that illness does not define them as a person. Practice gently encouraging them to participate, along with any positive adaptations, as needed. Keep it low key: “We can toss a soccer chair in the trunk just in case you need to take a break.”

article continues after advertisement
Validate the difficulties

While encouraging children to forge ahead, it is also essential that family members communicate their belief about the child's experience, including the severity of the pain. Taryn's story illustrates the importance of asking how the child feels and avoiding snap judgments. Given the invisibility of pain and the uniqueness of their situation (compared with peers), children will face disbelief from others.

Carve out moments to sit with your child and offer support. Practice putting words on their experience, without trying to problem-solve or encourage:

  • “That sounds really hard.”
  • “How frustrating.” “How sad.” and so on.
Naming emotions shows that you understand and helps them to develop ways to describe and understand their own experience.

Let your child know that you are able to handle hearing about difficulties. Children may or may not readily share, but will value the offer. Parents are in the position to provide unconditional support. Communicating openly and honestly in an age-appropriate way can also build trust and ease fears.

Self-care for parents

Imagining how your child may feel can build empathy; however, dwelling on it is destructive. Parents also need respite from thinking about pain. Research suggests that parental distress not only affects parents, but the child and entire family. [3]

Be deliberate in cultivating the positives in your own life. Engage in activities you find pleasurable, relaxing, and fulfilling. Look to and cultivate supportive relationships. Consider healthful choices that reduce your own vulnerability, such as by getting adequate sleep, nutrition, and exercise. Neglecting your own needs creates a negative feedback loop. In order to keep positive for your child, you, too, need to find ways to create reserves of positivity. Make time to do things you enjoy. Keep in mind that exercise and laughtercan release tension and fortify you.

Watch out for the “shoulds,” such as:

  • “I shouldn’t have fun if my child hurts.”
  • “I shouldn’t complain about how I feel …”
Instead, look for ways to keep your child’s medical condition from overwhelming your own life, relationships, and family. Sometimes this requires being deliberate about carving out time for intimacy (“date night”), as well as “family time,” in which family members can connect over activities that everyone can enjoy. Spending time with each family member also reduces the risks associated with “well children,” whose needs can be overshadowed by an ill sibling.

It is also vital to know your limits. Take “time outs” as needed. Do your best to figure out what is essential and to reward yourself along the way. Strive to be flexible, gentle, and understanding with yourself too.

The value of support

Despite your best efforts, at times you will likely struggle with feeling ineffective, frustrated, disappointed, angry, or anxious. There is no need to do this alone. Psychotherapy and support groups can offer support and coping skills to help you, your child, your relationship with a partner, or the family as a whole. One mother confided that her biggest regret was not seeking counseling to help family members cope with difficulties. Professionals can help parents and children alike to sort out their feelings and find strategies to navigate their lives.

You can also look to parents and children who are going through the same thing for practical suggestions and support. Knowing that you are not alone is invaluable. At the same time, be careful to limit the extent to which you or your child may identify with an “illness community,” as this can narrow one’s self-image. The goal is to figure out how to live as full and rich a life as possible. Connecting to the wider community (beyond illness) helps separate one’s identity from “illness” (which is just a facet of one’s experience). This is as important for a child as it is for parents and the entire family.


https://www.psychologytoday.com/blog/paintracking/201310/children-chronic-pain
 
Last edited:

playahaitian

Rising Star
Certified Pussy Poster
https://www.cnbc.com/2017/08/07/new-sickle-cell-anemia-drug-endari-by-emmanus-is-fda-approved.html

The story behind the new sickle cell drug that was 25 years in the making
  • Sickle cell affects nearly 100,000 people in the United States.
  • Endari has been approved for patients, the first approval for this rare blood disorder in nearly 20 years.
  • Before the FDA's approval, sickle cell patients most commonly were treated with a drug that's also used in chemotherapy.
Chris Morris, special to CNBC.com
Monday, 7 Aug 2017 | 9:51 AM ETCNBC.com
104274952-sickle_cell_from_timeline.530x298.jpg

Source: Recursion Pharmaceuticals
Sickle cell disease is a lifelong disorder in which red blood cells, normally round, are crescent- (or sickle-) shaped, due to abnormal hemoglobin. This can impede blood flow.
In early July the Food and Drug Administration approved the first new drug for sickle cell patients in nearly 20 years. It was a watershed moment for people who suffer from the rare blood disorder that can cause debilitating pain. And for one physician it was the end of a 25-year journey.

The drug, Endari, is made by Emmaus and has been approved for patients five years and older. It injects glutamine into red blood cells, reducing the likelihood they will clog and cause painful blockages in small blood vessels and, in some cases, organs.

Sickle cell disease primarily affects African Americans, Latinos and other minority groups. It's a lifelong disorder in which red blood cells, normally round, are crescent- (or sickle-) shaped, due to abnormal hemoglobin. That shape makes the cells less flexible, or more 'sticky,' which can impede blood flow. By injecting glutamine into the cells, Endari makes the cells less 'sticky.' It's not a permanent solution, but it does help reduce the pain.


"We knew this was not going to cure the disease, but improve the conditions [for patients]," says Yutaka Niihara, MD, CEO of Emmaus. "We're able to decrease the symptoms and make the circulation better."

Sickle cell affects about 100,000 people in the United States, a number that's dwarfed by people suffering from cancer, heart disease and other high-profile ailments. That number could actually be higher, but many patients are viewed as "drug seekers" by some members of the medical community, due to the severe pain they face. As a result, they may not be diagnosed with sickle cell.

More from Modern Medicine:
New hope for a vaccine to fight Gonorrhea
New tools to combat the organ transplant crisis
A.I.'s expanding role in medicine

Still, that official patient count made sickle cell an "orphan disease" in the eyes of most pharmaceutical companies, which ignored it for decades because of the perceived fear that development costs on any drugs would not be recouped.

A lifelong mission
Niihara first saw the disease in 1989, he says, when training in hemotology. He had planned to specialize in cancer, but after seeing sickle cell's impact on patients, he changed his focus to researching the disease.

He first approached the FDA with the research for what would become Endari in 2000 and was given a $1 million grant to begin a Phase 2 clinical study.

From there, he says, he planned to pass it on to an established pharmaceutical company to continue the research, but he couldn't find an interested company. As a result, he started Emmaus.

Now that Endari has received approval, he says, he intends to ensure it is an affordable drug so patients can relieve their suffering.

"Typically, the way pharmaceutical companies make money on a new medication is to charge enormous amounts of money for treatment," he says. "Treatment for an orphan [disease] can cost $200,000 to $300,000 per year. Some can be more. That's not our goal at all. We're going to try to keep our price of a fully dosed patient below $20K. We're sill finalizing pricing with our agency, but that's what I'm asking."

Emmaus, he says, has roughly an 85 percent margin on the product, so if it treats just 10
percent of the patients in the United States, it would result in more than $100 million in revenue.

"For a small biotech, that's big money," he says.

Should European approvals come, the market jumps to $2 billion, he says.

Future prospects
The approval of Endari has won praise from sickle cell advocacy groups, though they're encouraging federal regulators and drug makers to speed up the pace of treatment research for the disease.

"More effort and resources still need to be dedicated to nutritional supplementation studies aimed at establishing specific RDAs (recommended dietary allowances) for sickle cell patients, much like the specific RDAs developed for cystic fibrosis, pregnancy and growth within the general population," said Lanetta Bronté, president of the Foundation for Sickle Cell Disease Research.

Before the FDA's approval of Endari, sickle cell patients most commonly were treated with Hydroxyurea, a drug that's also used in chemotherapy. Endari, like any drug, has potential side effects. The FDA reported those could include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. But Niihara says, it doesn't have toxicity.

"As a physician who is always facing sickle cell patients, I appreciated [Hydroxyurea], but at the same time, I wanted to provide something that doesn't have toxicity — something where patients didn't have to worry about birth defects or ... worry they might develop cancer in the future."

Endari may have broken a long drought in sickle cell treatments, but it could have lots of company soon. As of last year, there were a dozen other drugs still in development for the disease.
 

playahaitian

Rising Star
Certified Pussy Poster
The story behind the new sickle cell drug that was 25 years in the making
  • Sickle cell affects nearly 100,000 people in the United States.
  • Endari has been approved for patients, the first approval for this rare blood disorder in nearly 20 years.
  • Before the FDA's approval, sickle cell patients most commonly were treated with a drug that's also used in chemotherapy.
Chris Morris, special to CNBC.com
Monday, 7 Aug 2017 | 9:51 AM ETCNBC.com
104274952-sickle_cell_from_timeline.530x298.jpg

Source: Recursion Pharmaceuticals
Sickle cell disease is a lifelong disorder in which red blood cells, normally round, are crescent- (or sickle-) shaped, due to abnormal hemoglobin. This can impede blood flow.
In early July the Food and Drug Administration approved the first new drug for sickle cell patients in nearly 20 years. It was a watershed moment for people who suffer from the rare blood disorder that can cause debilitating pain. And for one physician it was the end of a 25-year journey.

The drug, Endari, is made by Emmaus and has been approved for patients five years and older. It injects glutamine into red blood cells, reducing the likelihood they will clog and cause painful blockages in small blood vessels and, in some cases, organs.

Sickle cell disease primarily affects African Americans, Latinos and other minority groups. It's a lifelong disorder in which red blood cells, normally round, are crescent- (or sickle-) shaped, due to abnormal hemoglobin. That shape makes the cells less flexible, or more 'sticky,' which can impede blood flow. By injecting glutamine into the cells, Endari makes the cells less 'sticky.' It's not a permanent solution, but it does help reduce the pain.


"We knew this was not going to cure the disease, but improve the conditions [for patients]," says Yutaka Niihara, MD, CEO of Emmaus. "We're able to decrease the symptoms and make the circulation better."

Sickle cell affects about 100,000 people in the United States, a number that's dwarfed by people suffering from cancer, heart disease and other high-profile ailments. That number could actually be higher, but many patients are viewed as "drug seekers" by some members of the medical community, due to the severe pain they face. As a result, they may not be diagnosed with sickle cell.

More from Modern Medicine:
New hope for a vaccine to fight Gonorrhea
New tools to combat the organ transplant crisis
A.I.'s expanding role in medicine

Still, that official patient count made sickle cell an "orphan disease" in the eyes of most pharmaceutical companies, which ignored it for decades because of the perceived fear that development costs on any drugs would not be recouped.

A lifelong mission
Niihara first saw the disease in 1989, he says, when training in hemotology. He had planned to specialize in cancer, but after seeing sickle cell's impact on patients, he changed his focus to researching the disease.

He first approached the FDA with the research for what would become Endari in 2000 and was given a $1 million grant to begin a Phase 2 clinical study.

From there, he says, he planned to pass it on to an established pharmaceutical company to continue the research, but he couldn't find an interested company. As a result, he started Emmaus.

Now that Endari has received approval, he says, he intends to ensure it is an affordable drug so patients can relieve their suffering.

"Typically, the way pharmaceutical companies make money on a new medication is to charge enormous amounts of money for treatment," he says. "Treatment for an orphan [disease] can cost $200,000 to $300,000 per year. Some can be more. That's not our goal at all. We're going to try to keep our price of a fully dosed patient below $20K. We're sill finalizing pricing with our agency, but that's what I'm asking."

Emmaus, he says, has roughly an 85 percent margin on the product, so if it treats just 10
percent of the patients in the United States, it would result in more than $100 million in revenue.

"For a small biotech, that's big money," he says.

Should European approvals come, the market jumps to $2 billion, he says.

Future prospects
The approval of Endari has won praise from sickle cell advocacy groups, though they're encouraging federal regulators and drug makers to speed up the pace of treatment research for the disease.

"More effort and resources still need to be dedicated to nutritional supplementation studies aimed at establishing specific RDAs (recommended dietary allowances) for sickle cell patients, much like the specific RDAs developed for cystic fibrosis, pregnancy and growth within the general population," said Lanetta Bronté, president of the Foundation for Sickle Cell Disease Research.

Before the FDA's approval of Endari, sickle cell patients most commonly were treated with Hydroxyurea, a drug that's also used in chemotherapy. Endari, like any drug, has potential side effects. The FDA reported those could include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. But Niihara says, it doesn't have toxicity.

"As a physician who is always facing sickle cell patients, I appreciated [Hydroxyurea], but at the same time, I wanted to provide something that doesn't have toxicity — something where patients didn't have to worry about birth defects or ... worry they might develop cancer in the future."

Endari may have broken a long drought in sickle cell treatments, but it could have lots of company soon. As of last year, there were a dozen other drugs still in development for the disease.

https://www.cnbc.com/2017/08/07/new-sickle-cell-anemia-drug-endari-by-emmanus-is-fda-approved.html
 
Top